Üks Life4me+ peamiseid eesmärke on uute HIVi- ja muude sugulisel teel levivate nakkuste juhtumite, nagu ka C-hepatiiti ja tuberkuloosi nakatumise ennetamine.

Nutirakendus aitab luua kontakti arstide ja HIV positiivsete inimeste vahel. Nutirakendus aitab mugavalt organiseerida ravimite võtmise aegu, seadistada ainult Teile arusaadavad ja personaalseid meeldetuletusi, võimaldab saada arstilt tagasisidet ning panna aega vastuvõtule või analüüsidele.

Kõik uudised / Märts 2018

Arhiiv

✕

30 märts 2018

6544

Hornet is the leader in HIV prevention among social networks for gays and bisexuals

Hornet is the leader in HIV prevention among social networks for gays and bisexuals

This week, the global social network for gays and bisexuals Hornet made a statement that it was one of the first, 6 years ago, introduced the function of testing for HIV among its users - "Know Your Status". During this time, there were already 50 million interactions to ...

30 märts 2018

6227

South Africa: Rates of HIV infection among women are higher than in men, because fewer men are on treatment

South Africa: Rates of HIV infection among women are higher than in men, because fewer men are on treatment

South African scientists at the recent Conference on Retroviruses and Opportunistic Infections (CROI2018) suggested that the extremely high prevalence of HIV infection in women may be due to the fact that women are more likely to be diagnosed and start antiretroviral therapy ...

28 märts 2018

7108

Grindr app will remind you about HIV testing

Grindr app will remind you about HIV testing

The world's largest dating application for gays and bisexual men will complement its software with reminders about the HIV tests. Grindr expects to send users notifications about HIV testing every three to six months, simultaneously indicating the nearest testing point.

27 märts 2018

6726

CHMP recommended that the European Commission approve the antiretroviral drug Juluca

CHMP recommended that the European Commission approve the antiretroviral drug Juluca

The Committee for Medicinal Products for Human Use (CHMP) recommended that the European Commission approve the combined dolutegravir/rilpivirin (brand name: Juluca) ARV-drug with a fixed dosage (50 mg and 25 mg, respectively) for once-daily administration.

21 märts 2018

7093

Cats can aid development of antiviral drugs for people living with HIV

Cats can aid development of antiviral drugs for people living with HIV

HIV and the feline immunodeficiency virus (FIV) are similar in structure and action, but the latter has features that allow it to be resistant to certain HIV drugs. This phenomenon of resistance has been studied by scientists in order to develop a drug for multidrug-resistant ...

20 märts 2018

6838

The rate of HIV spread in Russia reached a maximum

The rate of HIV spread in Russia reached a maximum

According to the Ministry of Health, 88,600 new HIV cases were registered 2017 in Russia, and according to the other Russian authority Rospotrebnadzor (ed. “authority of epidemiology”), 104,400 cases. The difference between the two authorities was always present, since they ...

15 märts 2018

6098

A step forward to the vaccine against HIV

A step forward to the vaccine against HIV

Science is moving forward, and scientists are coming closer to the solution of the mystery of the 21st century - the vaccine against HIV. This time they modified the antibodies and increased their ability to neutralize HIV-1. New modified Tri-NAb antibodies are now capable ...

14 märts 2018

6301

Powerful new PrEP and treatment drug should be effective as a small weekly pill

Powerful new PrEP and treatment drug should be effective as a small weekly pill

MK-8591 to be taken into HIV treatment trials with another new drug, doravirine.

13 märts 2018

7383

Rapid testing of HIV and HBC/HVC in Portugal

Rapid testing of HIV and HBC/HVC in Portugal

On March 12, 2018, the Portuguese government authorized rapid testing for HIV and hepatitis B and C in pharmacies and laboratories without a doctor's prescription, according to the Ministry of Health. The decision will come into force 30 days after signing.

13 märts 2018

5960

Naltrexone helps ex-prisoners with substance use disorders succeed on HIV meds

Naltrexone helps ex-prisoners with substance use disorders succeed on HIV meds

Monthly injections of extended-release naltrexone is linked to viral suppression among this population. CROI2018

1 2